AIxCrypto Holdings, Inc. (AIXC) is a Financials stock trading at $1.06 (as of 2026-08-21), with a market capitalization of $21.45M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
AIxCrypto Holdings, Inc. is a clinical-stage therapeutics company developing cancer treatments for adult and pediatric patients. Its lead investigational small-molecule program, QN-302, is a G-quadruplexes (G4)-selective transcription inhibitor in Phase I for pancreatic cancer and other solid tumors, and it is also developing Pan-RAS for advanced solid tumors.
Understand AIxCrypto Holdings, Inc.: how it makes money
AIxCrypto Holdings develops cancer drug candidates, including its lead program QN-302, and generates value by advancing these clinical and preclinical therapies through trials.
As a clinical-stage therapeutics company with a Phase I lead asset, its profit trajectory is primarily driven by whether clinical development progresses successfully, rather than by established product revenue.
Business quality (Weak): Early-stage oncology pipeline with key development risk, and no disclosed segment revenue breakdown.
Bull case
QN-302 is in Phase I for pancreatic cancer and other solid tumors, which can create decision points for future development: Advancing a lead investigational program is a core path to future value creation if results support continued development.
Additional pipeline work includes Pan-RAS in preclinical development for advanced solid tumors: A broader pipeline can provide multiple shots on goal, even though early-stage.
Bear case
The company is clinical-stage and the lead program is only in Phase I, which is typically early in the risk curve: Clinical failure or lack of sufficient results can limit the ability to progress programs.
The latest quarter shows negative operating margin (operating_margin_pct: -1430.2) and revenue_b is listed as 0.0B: This suggests the business is not yet operating profitably, and ongoing development costs can pressure outcomes until programs advance.
Pan-RAS is preclinical, meaning results are not yet in clinical testing: Preclinical candidates can fail to translate into clinical benefit.